Angelini Ventures invests 3 million dollars in Freya Biosciences, biotech company focused on female infertility and microbiota role on reproductive and women’s health
Angelini Ventures, international venture capital company of Angelini Industries, has invested 3 million dolars in Freya Biosciences as part of a 38 million funding round, which is the “Series A round”. This is the first phase of growth for the company and it is carried out by Sofinnova Partners and OMX Ventures, together with Export and Investment Fund of Denmark, Mike Jafar Family Fund, CE-Ventures, Corundum Systems Biology and Indaco Venture Partners.
This investment is aimed at advancing clinical studies with a focus on female infertility, developing a digital data platform to define more targeted therapies, and strengthening the company’s teams. The investment will enable Freya Biosciences, startup based in Copenhagen that operates in the biotechnology sector with clinical research activities on female and reproductive health, to further develop its research on the effects of microbiota rebalancing on reproductive and women’s health.
The funding will support, in fact, the development of a microbial immunomodulating drug candidate derived from healthy female donors to resolve dysbiosis, a condition associated with infertility. The investment aligns with the growth and innovation strategy of Angelini Industries, a multinational industrial group. It is part of Angelini Ventures’ journey to identify and support innovative ideas in the life sciences field.
Angelini enters in Clinical research on female fertility
The investment by Angelini Ventures is significant as it marks the first time the group is entering clinical research on female fertility. This reflects a growing focus on women’s health and gender medicine, with a commitment to developing new, effective, and personalized therapeutic solutions that address the well-being needs of women, especially in the area of maternity.
Colleen Acosta, CEO, Freya Biosciences ApS says: “We are very excited to announce Freya’s Series A fundraise, with the support of this dedicated team of investors. Conditions that disproportionately and differently affect women have traditionally been underfunded in proportion to its burden on human health. Freya’s initial focus is on the millions of couples around the world that are struggling with infertility. This funding enables us to advance our groundbreaking immunotherapy platform targeting the vaginal microbiota and unlock its therapeutic potential in this area and beyond”.
Microbiota, a role in health and fertility
Freya Biosciences’ research focuses on the interaction between female fertility and the vaginal microbiota, with a specific emphasis on resolving dysbiosis, which is often associated with infertility. The company is developing a microbial immunomodulating drug candidate to restore microbiota balance in women with dysbiosis. Initial results from proof-of-concept clinical studies show the effectiveness of the drug candidate in restoring microbiota balance in women with dysbiosis within a few days.
The investment by Angelini Ventures and other partners reflects a growing interest in innovative approaches to address women’s health issues, particularly in the field of fertility and microbiota research. This investment is expected to contribute to the development of new therapeutic solutions and advance the understanding of the role of the vaginal microbiota in women’s health and fertility.
Sergio Marullo di Condojanni, CEO of Angelini Industries confirms: “For the first time, thanks to this investment by Angelini Ventures, our Group is entering clinical research on female fertility. Women’s health and, more generally, gender medicine deserve the utmost attention. That’s why we have chosen to fund this company committed to developing new, effective, and personalized therapeutic solutions that address the well-being needs of women, especially the desire for maternity. Our commitment in this area is part of the overall strategy of the Group to be attentive to the needs of individuals and families in the various sectors it operates”.